Related references
Note: Only part of the references are listed.Computational approaches to disease-gene prediction: rationale, classification and successes
Rosario M. Piro et al.
FEBS JOURNAL (2012)
Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial
Michelle A. Albert et al.
AMERICAN HEART JOURNAL (2011)
Cardiovascular Pharmacogenomics
Dan M. Roden et al.
CIRCULATION RESEARCH (2011)
Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study
L. A. Donnelly et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The Impact of Pharmacogenomics on the Management of Cardiac Disease
N. L. Pereira et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The Emerging Role of Electronic Medical Records in Pharmacogenomics
R. A. Wilke et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Statin-induced myopathy: a review and update
Thura T. Abd et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Genetics and Variable Drug Response
Russell A. Wilke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance
Steven P. Kennedy et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Statins and safety: can we finally be reassured?
Payal Kohli et al.
LANCET (2011)
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
R. Bulbulia et al.
LANCET (2011)
ASSOCIATION OF COMMON VARIANTS IN THE HUMAN EYES SHUT ORTHOLOG (EYS) WITH STATIN-INDUCED MYOPATHY: EVIDENCE FOR ADDITIONAL FUNCTIONS OF EYS
Paul J. Isackson et al.
MUSCLE & NERVE (2011)
Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy
Amy Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Differences in Candidate Gene Association between European Ancestry and African American Asthmatic Children
Tesfaye M. Baye et al.
PLOS ONE (2011)
Cerivastatin, genetic variants, and the risk of rhabdomyolysis
Kristin D. Marciante et al.
PHARMACOGENETICS AND GENOMICS (2011)
Integrative genomics strategies to elucidate the complexity of drug response
Andrew Kasarskis et al.
PHARMACOGENOMICS (2011)
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins
Grant T. Generaux et al.
XENOBIOTICA (2011)
Genome-Wide Association Study of Coronary Heart Disease and Its Risk Factors in 8,090 African Americans: The NHLBI CARe Project
Guillaume Lettre et al.
PLOS GENETICS (2011)
Prioritizing GWAS Results: A Review of Statistical Methods and Recommendations for Their Application
Rita M. Cantor et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
Combined Influence of LDLR and HMGCR Sequence Variation on Lipid-Lowering Response to Simvastatin
Lara M. Mangravite et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study
Luca Puccetti et al.
ATHEROSCLEROSIS (2010)
Pitavastatin A New HMG-CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia
Haniyyah Ahmad et al.
CARDIOLOGY IN REVIEW (2010)
UDP-Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo
S. Riedmaier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Transporter Pharmacogenetics and Statin Toxicity
M. Niemi
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin
B. Tomlinson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
The effects of statins on skeletal muscle strength and exercise performance
Guru M. Krishnan et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Clinical assessment incorporating a personal genome
Euan A. Ashley et al.
LANCET (2010)
Statistical analysis strategies for association studies involving rare variants
Vikas Bansal et al.
NATURE REVIEWS GENETICS (2010)
VIEWPOINT Missing heritability and strategies for finding the underlying causes of complex disease
Evan E. Eichler et al.
NATURE REVIEWS GENETICS (2010)
Muscle toxicity with statins
Karin Hedenmalm et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis
Ruediger Kaspera et al.
PHARMACOGENETICS AND GENOMICS (2010)
Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins
Kuo-Liong Chien et al.
PHARMACOGENOMICS (2010)
Mapping genes that predict treatment outcome in admixed populations
T. M. Baye et al.
PHARMACOGENOMICS JOURNAL (2010)
ABCG2: A perspective
Robert W. Robey et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Antiretroviral and Statin Drug-Drug Interactions
Gretchen M. Ray
CARDIOLOGY IN REVIEW (2009)
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Using biological networks to search for interacting loci in genome-wide association studies
Mathieu Emily et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2009)
Possible Mechanisms Underlying Statin-Induced Skeletal Muscle Toxicity in L6 Fibroblasts and in Rats
Mai Itagaki et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2009)
The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects
Deepak Voora et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The HMG-CoA Reductase Gene and Lipid and Lipoprotein Levels: the Multi-Ethnic Study of Atherosclerosis
Yi-Chun Chen et al.
LIPIDS (2009)
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors
Christopher Rowan et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simastatin
Jenni E. Keskitalo et al.
PHARMACOGENOMICS (2009)
Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy
Tomomi Furihata et al.
PHARMACOGENOMICS JOURNAL (2009)
Pharmacogenomic insights into treatment and management of statin-induced myopathy
Bas J. M. Peters et al.
GENOME MEDICINE (2009)
Database mining for selection of SNP markers useful in admixture mapping
Tesfaye M. Baye et al.
BIODATA MINING (2009)
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER
Eliana Polisecki et al.
ATHEROSCLEROSIS (2008)
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment
Ronald M. Krauss et al.
CIRCULATION (2008)
Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme a reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin
Marisa Wong Medina et al.
CIRCULATION (2008)
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
Pertti J. Neuvonen et al.
CLINICAL PHARMACOKINETICS (2008)
Genome-wide association studies: potential next steps on a genetic journey
Mark I. McCarthy et al.
HUMAN MOLECULAR GENETICS (2008)
Opportunities for enhancing the FDA guidance on pharmacovigilance
Bruce M. Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Genome-wide analysis of transcript isoform variation in humans
Tony Kwan et al.
NATURE GENETICS (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Statin Induced Myopathy and Myalgia: Time Trend Analysis and Comparison of Risk Associated with Statin Class from 1991-2006
Mariam Molokhia et al.
PLOS ONE (2008)
The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care
Luis Alberto Garcia-Rodriguez et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
A paucimorphic variant in the HMO-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study
Louise A. Donnelly et al.
PHARMACOGENETICS AND GENOMICS (2008)
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: Are we there yet?
Minoli A. Perera et al.
PHARMACOTHERAPY (2008)
Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers
Kazuho Sakamoto et al.
FASEB JOURNAL (2007)
Effect of coenzyme Q10 supplementation on Siwastatin-induced myalgia
Joanna A. Young et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Russell A. Wilke et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
CYP2D6*4 polymorphism is associated with statin-induced muscle effects
Tony N. Frudakis et al.
PHARMACOGENETICS AND GENOMICS (2007)
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population
David L. McClure et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2007)
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis
Charles R. Harper et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Genetic determinants of statin intolerance
Jisun Oh et al.
LIPIDS IN HEALTH AND DISEASE (2007)
Safety and efficacy of statins in Asians
James K. Liao
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Discovery of tissue-specific exons using comprehensive human exon microarrays
Tyson A. Clark et al.
GENOME BIOLOGY (2007)
Assessing the conservation of mammalian gene expression using high-density exon arrays
Yi Xing et al.
MOLECULAR BIOLOGY AND EVOLUTION (2007)
Risk factors for statin-associated rhabdomyolysis
Stephanie Schech et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Genetic architecture of complex traits in plants
James B. Holland
CURRENT OPINION IN PLANT BIOLOGY (2007)
A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
Reijo Laaksonen et al.
PLOS ONE (2006)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Genetic risk factors associated with lipid-lowering drug-induced myopathies
Georgirene D. Vladutiu et al.
MUSCLE & NERVE (2006)
Highly parallel genomic assays
Jian-Bing Fan et al.
NATURE REVIEWS GENETICS (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Statin safety: Lessons from new drug applications for marketed statins
TA Jacobson
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Statin safety: A systematic review
M Law et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
JM McKenney et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
An assessment of statin safety by muscle experts
PD Thompson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Opinion - Mendelian disorders deserve more attention
SE Antonarakis et al.
NATURE REVIEWS GENETICS (2006)
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
E Bruckert et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
TR Pedersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Combinatorial pharmacogenetics
RA Wilke et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein
S Matzno et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2005)
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment
M Fiegenbaum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Differential association between statin exposure and elevated levels of creatine kinase
J Chan et al.
ANNALS OF PHARMACOTHERAPY (2005)
Safety of high-dose atorvastatin therapy
DD Waters
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells
J Sacher et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion- transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein
S Matsushima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage
RA Wilke et al.
PHARMACOGENETICS AND GENOMICS (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis
H Ozaki et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2005)
Statin-associated neuromyotoxicity
SK Baker et al.
DRUGS OF TODAY (2005)
Transporters and drug therapy: Implications for drug disposition and disease
RH Ho et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems
H Sinzinger et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin
C Ishikawa et al.
JOURNAL OF HUMAN GENETICS (2004)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial
JA de Lemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
The future of association studies: Gene-based analysis and replication
BM Neale et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
DJ Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone
TE Johnson et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
DW Schneck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
J Mwinyi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors
JA Tobert
NATURE REVIEWS DRUG DISCOVERY (2003)
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6
T Prueksaritanont et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Response to The efficacy of simvastatin is not influenced by CYP2D6 polymorphism by Geisel et al
AB Mulder et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Statin-associated myopathy
PD Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Risk for myopathy with statin therapy in high-risk patients
CM Ballantyne et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Statin-associated myopathy with normal creatine kinase levels
PS Phillips et al.
ANNALS OF INTERNAL MEDICINE (2002)
ACC/AHA/NHLBI clinical advisory on the use and safety of statins
RC Pasternak et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Mechanistic studies on metabolic interactions between gemfibrozil and statins
T Prueksaritanont et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Mapping and analysis of quantitative trait loci in experimental populations
RW Doerge
NATURE REVIEWS GENETICS (2002)
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin
AB Mulder et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
